CL2014003232A1 - Formulaciones y métodos para la administración vaginal de antiprogestinas. - Google Patents

Formulaciones y métodos para la administración vaginal de antiprogestinas.

Info

Publication number
CL2014003232A1
CL2014003232A1 CL2014003232A CL2014003232A CL2014003232A1 CL 2014003232 A1 CL2014003232 A1 CL 2014003232A1 CL 2014003232 A CL2014003232 A CL 2014003232A CL 2014003232 A CL2014003232 A CL 2014003232A CL 2014003232 A1 CL2014003232 A1 CL 2014003232A1
Authority
CL
Chile
Prior art keywords
antiprogestins
formulations
methods
vaginal administration
vaginal
Prior art date
Application number
CL2014003232A
Other languages
English (en)
Spanish (es)
Inventor
Joseph S Podolsky
Kuang Hsu
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2014003232A1 publication Critical patent/CL2014003232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014003232A 2012-05-31 2014-11-27 Formulaciones y métodos para la administración vaginal de antiprogestinas. CL2014003232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
CL2014003232A1 true CL2014003232A1 (es) 2015-03-13

Family

ID=48614182

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003232A CL2014003232A1 (es) 2012-05-31 2014-11-27 Formulaciones y métodos para la administración vaginal de antiprogestinas.

Country Status (22)

Country Link
US (1) US10328022B2 (OSRAM)
EP (1) EP2854763B1 (OSRAM)
JP (1) JP6341910B2 (OSRAM)
KR (1) KR102127348B1 (OSRAM)
CN (1) CN104334158B (OSRAM)
AU (1) AU2013267359C1 (OSRAM)
BR (1) BR112014029131B1 (OSRAM)
CA (1) CA2872644A1 (OSRAM)
CL (1) CL2014003232A1 (OSRAM)
CO (1) CO7141411A2 (OSRAM)
CR (1) CR20140567A (OSRAM)
EA (1) EA030444B1 (OSRAM)
ES (1) ES2701400T3 (OSRAM)
IL (1) IL235450B (OSRAM)
IN (1) IN2014DN10548A (OSRAM)
MX (2) MX382986B (OSRAM)
NZ (1) NZ702467A (OSRAM)
PH (1) PH12014502516B1 (OSRAM)
SG (2) SG11201407397WA (OSRAM)
UA (1) UA114106C2 (OSRAM)
WO (1) WO2013181449A1 (OSRAM)
ZA (1) ZA201408262B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN111840246A (zh) 2014-05-05 2020-10-30 艾尔建制药国际有限公司 用于抗孕激素的阴道递送的制剂和方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US11623008B2 (en) 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
AU2015336065A1 (en) * 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
EP4585211A3 (en) * 2017-04-14 2025-10-22 Capsugel Belgium NV Pullulan capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
WO1996023503A1 (de) 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
ATE194358T1 (de) 1996-05-01 2000-07-15 Us Gov Health & Human Serv 21-substituierte progesteron derivate als antigestagene
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6982091B2 (en) 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
DK1265911T3 (da) 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
IN191020B (OSRAM) 2000-03-28 2003-09-13 Dabur Res Foundation
ES2253443T3 (es) 2000-10-18 2006-06-01 Schering Aktiengesellschaft Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
CN1954807A (zh) 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
KR20070114187A (ko) 2005-03-22 2007-11-29 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜의 투약 방법
EP1874732A1 (en) 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
EP1940413A1 (en) * 2005-09-29 2008-07-09 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
PL2078032T3 (pl) 2006-10-24 2018-01-31 Repros Therapeutics Inc Kompozycje i sposoby do hamowania proliferacji endometrium
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
DK2197415T3 (da) 2007-09-20 2014-05-26 Lapidot Medical Imp And Marketing Ltd Sammensætninger og midler til at behandle uterusleiomyomer, leiomyom, myom, uterusfibroid, endometriose, adenomyose og beslægtede forstyrrelser med mifepriston
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
WO2011039680A1 (en) * 2009-09-29 2011-04-07 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
MX2019003467A (es) 2019-06-06
SG11201407397WA (en) 2014-12-30
ZA201408262B (en) 2015-12-23
SG10201704858PA (en) 2017-07-28
IN2014DN10548A (OSRAM) 2015-08-21
HK1206622A1 (en) 2016-01-15
IL235450B (en) 2020-02-27
MX363640B (es) 2019-03-28
CN104334158B (zh) 2018-08-10
EP2854763A1 (en) 2015-04-08
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
MX2014014054A (es) 2015-02-12
CN104334158A (zh) 2015-02-04
KR20150014928A (ko) 2015-02-09
JP6341910B2 (ja) 2018-06-13
CR20140567A (es) 2015-03-09
BR112014029131B1 (pt) 2021-03-09
PH12014502516A1 (en) 2015-01-12
BR112014029131A2 (pt) 2018-05-29
US20150111862A1 (en) 2015-04-23
MX382986B (es) 2025-03-13
AU2013267359A1 (en) 2014-11-20
PH12014502516B1 (en) 2015-01-12
US10328022B2 (en) 2019-06-25
ES2701400T3 (es) 2019-02-22
AU2013267359C1 (en) 2016-09-29
JP2015518052A (ja) 2015-06-25
CA2872644A1 (en) 2013-12-05
EP2854763B1 (en) 2018-09-26
UA114106C2 (xx) 2017-04-25
AU2013267359B2 (en) 2016-05-26
CO7141411A2 (es) 2014-12-12
EA201492290A1 (ru) 2015-03-31
EA030444B1 (ru) 2018-08-31
WO2013181449A1 (en) 2013-12-05
IL235450A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
IL285474A (en) Anti- pdl1 antibody compositions
IL274881A (en) Anti-EGFR antibody and drug conjugate formulations
IL239022B (en) Tetracycline topical formulations, preparation and uses thereof
DK3061454T3 (da) Parasitiske orale veterinærsammensætninger omfattende systemisk-virkende aktivstoffer, fremgangsmåder og anvendelser deraf
HUE047782T2 (hu) Gyógyászatilag aktív vegyületek és alkalmazási eljárásaik
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
BR112014009634A2 (pt) preparação e agente terapêutico
PH12019500176B1 (en) Heterocyclic compounds and ther uses
EP2953618A4 (en) MANIPULATION-SAFE PHARMACEUTICAL FORMULATIONS
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
ME03483B (me) Amorfni letermovir i njegove čvrste farmaceutske formulacije za oralno davanje
IL245479B (en) Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
PL2922576T3 (pl) Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej
HRP20191361T1 (hr) Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe
PL2729008T3 (pl) Systemy, sposoby i formulacje do leczenia raka
PL3064491T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
EP2985029A4 (en) MEDICATION FOR EXTERNAL USE IN CLEANING AND CARE OF OVARIES, VAGS AND VULVES
PT2525827T (pt) Formulações farmacêuticas de loratadina para encapsulação e combinações das mesmas
BR112015010428A2 (pt) agente terapêutico para distúrbios ceratoconjuntivos
BR112015002867A2 (pt) dispositivos e métodos para fixar dispositivos médicos dentro de uma anatomia.
HUE071419T2 (hu) Gyógyászati szénhidrát készítmény terápiás alkalmazásra
BR112014017217A8 (pt) agente e composição farmacêutica